Landmark study with PCSK9 inhibitor will change clinical practice - PACE-CME

Landmark study with PCSK inhibitor will change clinical practice

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

E-counselling improves adherence in hypertensives
E-counselling improves adherence in hypertensives
ACC.17
E-counselling improves adherence in hypertensives
- Dr. Rob Nolan
PCI-registry-based trial shows that IFR is non-inferior to FFR, with reduced discomfort and stenting
PCI-registry-based trial shows that IFR is non-inferior to FFR, with reduced discomfort and stenting
ACC.17
PCI-registry-based trial shows that IFR is non-inferior to FFR, with reduced discomfort and stenting
The implications of PCSK9 outcome trials for GPs
The implications of PCSK9 outcome trials for GPs
ACC.17
The implications of PCSK9 outcome trials for GPs
- Prof. Richard Hobbs, MD
Identification of patients who will benefit is important after FOURIER
Identification of patients who will benefit is important after FOURIER
ACC.17
Identification of patients who will benefit is important after FOURIER
- Prof. Ulf Landmesser